2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,A...2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,ASH)会议中关于CAR-T细胞治疗血液恶性肿瘤的研究进展做一综述。展开更多
2016年是血液恶性肿瘤免疫治疗取得众多进展的一年,其中细胞免疫治疗和抗体免疫治疗尤为突出。本文将对近一年来已发表的以及第58届美国血液病学会（American Society of Hematology,ASH）会议中关于血液恶性肿瘤免疫治疗的最新进展作...2016年是血液恶性肿瘤免疫治疗取得众多进展的一年,其中细胞免疫治疗和抗体免疫治疗尤为突出。本文将对近一年来已发表的以及第58届美国血液病学会（American Society of Hematology,ASH）会议中关于血液恶性肿瘤免疫治疗的最新进展作一综述。展开更多
1文献来源Prebet T,Sun Z,Ketterling RP,et al.Azacitidine with or without Entinostat for the treatmentof therapy-related myeloid neoplasm：Further resultsof the E1905 North American Leukemia IntergroupStudy[J].Br J Haem...1文献来源Prebet T,Sun Z,Ketterling RP,et al.Azacitidine with or without Entinostat for the treatmentof therapy-related myeloid neoplasm：Further resultsof the E1905 North American Leukemia IntergroupStudy[J].Br J Haematol,2016,172（3）：384-391.2证据水平1b。3背景·治疗相关髓系肿瘤（therapy related myeloidneoplasm,t-MN）,展开更多
1 文献来源
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy： Results of the multicenter...1 文献来源
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy： Results of the multicenter randomized Acute Leukemia French Association （ALFA） 9803 trial [ J]. Blood, 2007, 109（12） ：5129-5135.展开更多
1文献来源
Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia （Ph＋ALL） [J]....1文献来源
Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia （Ph＋ALL） [J]. Cancer, 2007,109（10）：2068-2076.展开更多
1 文献来源
M4 acute myeloid leukemia：The role of eosinophilia and cytogenetics in treatment response and survival The GIMEMA experience [J]. Haematologica, 2008, 93（7） ： 1025 -1032.
1 文献来源
Btichner T, Berdel WE, Haferlach C, et al, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia： A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Onc...1 文献来源
Btichner T, Berdel WE, Haferlach C, et al, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia： A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Oncol, 2009,27（1）：61-69.展开更多
1文献来源
Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission： Cancer and Leukemia Group B Study 9720. [J]. J Cl...1文献来源
Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission： Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008,12（26）：4934-4939.展开更多
1文献来源
Pigneux A, Harousseau JL, Witz F, et al. Addition of Lomustine to Idarubicin and Cytarabine improves the outcome of elderly patients with De Novo acute myeloid leukemia： A report from the GOELAMS[J]. J Cl...1文献来源
Pigneux A, Harousseau JL, Witz F, et al. Addition of Lomustine to Idarubicin and Cytarabine improves the outcome of elderly patients with De Novo acute myeloid leukemia： A report from the GOELAMS[J]. J Clin Oncol, 2010,28（18）：3028-3034.展开更多
1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia（SORAML）：A multicentre,phase 2...1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia（SORAML）：A multicentre,phase 2,randomised controlled tria[lJ].Lancet Oncol,2015,16（16）：1691-1699.2证据水平1b。3背景·目前急性髓系白血病（acute myeloidleukemia,AML）的标准治疗方案是阿糖胞苷联合葸环类或者蒽醌类药物，展开更多
1文献来源
Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and...1文献来源
Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome [J]. Blood, 2008,112（5）：1638-1645.展开更多
1 文献来源
Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival： Treatment results of 2 169 unselected pediatric and ado...1 文献来源
Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival： Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J]. Blood,2008,111（9）：4477-4489.展开更多
文摘2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,ASH)会议中关于CAR-T细胞治疗血液恶性肿瘤的研究进展做一综述。
文摘1文献来源Prebet T,Sun Z,Ketterling RP,et al.Azacitidine with or without Entinostat for the treatmentof therapy-related myeloid neoplasm：Further resultsof the E1905 North American Leukemia IntergroupStudy[J].Br J Haematol,2016,172（3）：384-391.2证据水平1b。3背景·治疗相关髓系肿瘤（therapy related myeloidneoplasm,t-MN）,
文摘1 文献来源
Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy： Results of the multicenter randomized Acute Leukemia French Association （ALFA） 9803 trial [ J]. Blood, 2007, 109（12） ：5129-5135.
文摘1文献来源
Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia （Ph＋ALL） [J]. Cancer, 2007,109（10）：2068-2076.
文摘1 文献来源
M4 acute myeloid leukemia：The role of eosinophilia and cytogenetics in treatment response and survival The GIMEMA experience [J]. Haematologica, 2008, 93（7） ： 1025 -1032.
文摘1 文献来源
Btichner T, Berdel WE, Haferlach C, et al, Age-related risk profile and chemotherapy dose response in acute myeloid leukemia： A study by the German Acute Myeloid Leukemia Cooperative Group [J]. J Clin Oncol, 2009,27（1）：61-69.
文摘1文献来源
Low-dose Interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission： Cancer and Leukemia Group B Study 9720. [J]. J Clin Oncol, 2008,12（26）：4934-4939.
文摘1文献来源
Pigneux A, Harousseau JL, Witz F, et al. Addition of Lomustine to Idarubicin and Cytarabine improves the outcome of elderly patients with De Novo acute myeloid leukemia： A report from the GOELAMS[J]. J Clin Oncol, 2010,28（18）：3028-3034.
文摘1文献来源Rollig C,Serve H,Hüttmann A,et al.Addition of Sorafenib versus placebo to standard therapy in patients aged60 years or younger with newly diagnosed acute myeloidleukaemia（SORAML）：A multicentre,phase 2,randomised controlled tria[lJ].Lancet Oncol,2015,16（16）：1691-1699.2证据水平1b。3背景·目前急性髓系白血病（acute myeloidleukemia,AML）的标准治疗方案是阿糖胞苷联合葸环类或者蒽醌类药物，
文摘1文献来源
Faderl S, Ravandi F, Huang X, et al. A randomized study of Clofarabine versus Clofarabine plus low-dose Cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome [J]. Blood, 2008,112（5）：1638-1645.
文摘1 文献来源
Moricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival： Treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 [J]. Blood,2008,111（9）：4477-4489.
